Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Therapeutics Reports 35% Total Revenue Growth in First Quarter 2010
Strong Domestic Sales of ORTHOVISC(R) Drive 18% Organic Product Growth; Company Completes Initial Steps in FAB Integration Plan
View HTML
Toggle Summary Anika Therapeutics Announces Date of First-Quarter 2010 Financial Results Conference Call
Anika Therapeutics Announces Date of First-Quarter 2010 Financial Results Conference Call BEDFORD, Mass., May 03, 2010 (BUSINESS WIRE) --Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its first-quarter 2010 financial results after the close of the market on Monday,
View HTML
Toggle Summary Anika Therapeutics Reports 18% Revenue Growth in Fourth-Quarter 2009
Domestic Unit Sales of ORTHOVISC(R) Grow to Record Quarterly LevelJoint Health Revenue Increases 17% in Fourth Quarter
View HTML
Toggle Summary Anika Therapeutics Announces Date of Fourth-Quarter and Year-End 2009 Financial Results Conference Call
Anika Therapeutics Announces Date of Fourth-Quarter and Year-End 2009 Financial Results Conference Call BEDFORD, Mass., Mar 11, 2010 (BUSINESS WIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its fourth-quarter and year-end 2009 financial results after the
View HTML
Toggle Summary Anika Therapeutics to Webcast Presentation at Canaccord Adams Musculoskeletal Conference
Presentation to be Webcast live on March 9 at 9:00 a.m. CT
View HTML
Toggle Summary Anika Therapeutics to Discuss Acquisition of Fidia Advanced Biopolymers During Special Conference Call Today
Call to be Webcast at 10:00 a.m. ET
View HTML
Toggle Summary Anika Therapeutics Acquires Fidia Advanced Biopolymers: A Leading Innovator in Hyaluronic Acid Based Tissue Engineered Products
Acquisition Provides Novel Technology Platform for Growth & Broadens Anika's Product Portfolio and Development PipelineCompany to Develop Direct Sales Capability for MONOVISC(TM) and FAB Products
View HTML
Toggle Summary Anika Therapeutics Receives European CE Mark Approval for "ELEVESS Light"
Company Expands Aesthetic Franchise with New Product Used to Treat Fine Lines and Wrinkles Plans European Launch in Early 2010
View HTML
Toggle Summary Anika Therapeutics Reports 17% Revenue Growth in Third-Quarter 2009
Net Income Increases 37%
View HTML
Toggle Summary Anika Therapeutics Announces Date of Third Quarter 2009 Financial Results Conference Call
Anika Therapeutics Announces Date of Third Quarter 2009 Financial Results Conference Call BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 13, 2009-- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its third-quarter 2009 financial results after the close of the market on
View HTML